These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7986740)

  • 1. Immunoreactive interleukin-6 and C-reactive protein in plasma cell disorders.
    Smith SR; Morgan L
    Br J Haematol; 1994 Aug; 87(4):883-4. PubMed ID: 7986740
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis.
    Tienhaara A; Pulkki K; Mattila K; Irjala K; Pelliniemi TT
    Br J Haematol; 1994 Feb; 86(2):391-3. PubMed ID: 8199033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of patients with monoclonal gammopathy of undetermined significance is mandatory for a reliable use of interleukin-6 and other nonspecific multiple myeloma serum markers.
    Greco C; Ameglio F; Alvino S; Cianciulli AM; Giovannelli M; Mattei F; Vitelli G; Venturo I; Lopez M; Gandolfo GM
    Acta Haematol; 1994; 92(1):1-7. PubMed ID: 7985475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are serum interleukin-6 levels always useful for differentiating monoclonal gammopathies in unselected patients?
    Greco C; Vitelli G; Cianciulli AM; Alvino S; Gandolfo GM; Ameglio F
    Blood; 1992 Apr; 79(8):2173-4. PubMed ID: 1562744
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias.
    Ohtani K; Ninomiya H; Hasegawa Y; Kobayashi T; Kojima H; Nagasawa T; Abe T
    Br J Haematol; 1995 Sep; 91(1):116-20. PubMed ID: 7577617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum neural cell adhesion molecule in multiple myeloma and other plasma cell disorders.
    Smith SR; Auerbach B; Morgan L
    Br J Haematol; 1996 Jan; 92(1):67-70. PubMed ID: 8562413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of serum IL-6 level in monoclonal gammopathies.
    DuVillard L; Guiguet M; Casasnovas RO; Caillot D; Monnier-Zeller V; Bernard A; Guy H; Solary E
    Br J Haematol; 1995 Feb; 89(2):243-9. PubMed ID: 7873373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis.
    Koskela K; Pelliniemi TT; Rajamäki A; Pulkki K; Remes K
    Eur J Haematol; 2000 Jul; 65(1):52-6. PubMed ID: 10914939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.
    Bataille R; Jourdan M; Zhang XG; Klein B
    J Clin Invest; 1989 Dec; 84(6):2008-11. PubMed ID: 2592570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum interleukin-11 in plasma-cell dyscrasias.
    Stasi R; Brunetti M; Bussa S; Catucci AE; Pagano A; Amadori S
    Am J Hematol; 1996 Nov; 53(3):206-7. PubMed ID: 8895699
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum beta 2-microglobulin in patients with monoclonal gammopathies.
    Di Giovanni S; Valentini G; Ravazzolo E; Carducci P; Giallonardo P; Maschio C
    Int J Biol Markers; 1987; 2(3):169-72. PubMed ID: 3131451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for multiple myeloma.
    Reibnegger G; Fuchs D; Wachter H
    Blood; 1994 Aug; 84(4):1350-1. PubMed ID: 8049453
    [No Abstract]   [Full Text] [Related]  

  • 13. Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance.
    Bladé J; Filella X; Montoto S; Bosch F; Rosiñol L; Coca F; Giné E; Nadal E; Aymerich M; Rozman M; Montserrat E
    Br J Haematol; 2002 May; 117(2):387-9. PubMed ID: 11972522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acute phase proteins in monoclonal gammapathies].
    Dubost JJ; Ristori JM; Soubrier M; Ruivard M; Sauvezie B
    Pathol Biol (Paris); 1991 Oct; 39(8):769-73. PubMed ID: 1722302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 serum levels in patients with multiple myeloma.
    Emile C; Fermand JP; Danon F
    Br J Haematol; 1994 Feb; 86(2):439-40. PubMed ID: 8199045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [IL-6, p53 and proto-oncogene c-myc play different roles as biological markers of plasma cell dyscrasias].
    Alvino S; Marcucci M; Canzoniere D; Mosiello A; Del Monte G; Venturo I; Rinaldi M; Gandolfo GM; Lopez M; Greco C
    Clin Ter; 1999; 150(3):197-202. PubMed ID: 10528431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of C-reactive protein as a prognostic indicator in advanced cancer.
    Mahmoud FA; Rivera NI
    Curr Oncol Rep; 2002 May; 4(3):250-5. PubMed ID: 11937016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum oncostatin M in multiple myeloma: association with prognostic factors.
    Koskela K; Pelliniemi TT; Remes K; Rajamäki A; Pulkki K
    Br J Haematol; 1997 Jan; 96(1):158-60. PubMed ID: 9012701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum beta 2 microglobulin in multiple myeloma and related plasma cell dyscrasias.
    Pasquini E; Tiraferri E; Fattori PP; Fabbri I; Gobbi M
    Haematologica; 1987; 72(1):17-21. PubMed ID: 3108090
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.
    Thompson MA; Witzig TE; Kumar S; Timm MM; Haug J; Fonseca R; Greipp PR; Lust JA; Rajkumar SV
    Br J Haematol; 2003 Oct; 123(2):305-8. PubMed ID: 14531913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.